Linsitinib (OSI-906)

For research use only.

Catalog No.S1091

91 publications

Linsitinib (OSI-906) Chemical Structure

CAS No. 867160-71-2

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 186 In stock
EUR 167 In stock
EUR 265 In stock
EUR 707 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Linsitinib (OSI-906) has been cited by 91 publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk M4\1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXuWlJKSzVyPUCuNFI5ODZizszN MoLwV2FPT0WU
KS-1 NFfGS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjmTWM2OD1yLkCzPFM2KM7:TR?= NELYWJNUSU6JRWK=
TE-11 M2jZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;qTWM2OD1yLkC3PFIzKM7:TR?= NHP0PZNUSU6JRWK=
EW-1 NUjFTWNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\HbFNpUUN3ME2wMlA5PTh3IN88US=> M1XxT3NCVkeHUh?=
HMV-II NFnyR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XL[WlEPTB;MD6wPFg1PiEQvF2= M132e3NCVkeHUh?=
COLO-205 MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TGdWlEPTB;MD6xNFQ2PCEQvF2= MUXTRW5ITVJ?
ES1 NF;NS|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7UbVFKSzVyPUCuNVA3QTZizszN MYrTRW5ITVJ?
GDM-1 MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf5TWM2OD1yLkGzOlczKM7:TR?= NXLZZlk6W0GQR1XS
ML-2 MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrKeoFmUUN3ME2wMlE2QDl4IN88US=> M163NXNCVkeHUh?=
Saos-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj3TWM2OD1yLkG2OVI3KM7:TR?= NHn5OHlUSU6JRWK=
NCI-H1355 NXrvbIJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF35TXFKSzVyPUCuNVgyOzVizszN NFy1TmpUSU6JRWK=
G-401 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\IT252UUN3ME2wMlE5OjNizszN MlWyV2FPT0WU
EW-16 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7ZR5RKSzVyPUCuNVg4PzdizszN M1;uPXNCVkeHUh?=
EW-7 M{HvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH3cmw4UUN3ME2wMlE5QDhzIN88US=> NVLSeJBbW0GQR1XS
NCI-H727 NYD2SlRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfyTWM2OD1yLkG5O|k1KM7:TR?= MnLIV2FPT0WU
LCLC-97TM1 NHLMSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fo[GlEPTB;MD6yNFk2PSEQvF2= NWDLWXNDW0GQR1XS
NCI-H650 M4fKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMkGzPFQh|ryP M{WzTnNCVkeHUh?=
NCI-H2122 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\vNGdKSzVyPUCuNlMzQTlizszN MlnlV2FPT0WU
SK-N-DZ NYK5T4FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[xV5ZKSzVyPUCuNlM3QThizszN MVPTRW5ITVJ?
HT-29 MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMkSyOFgh|ryP M1LhbHNCVkeHUh?=
LB771-HNC NUXhcZRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;rTWM2OD1yLkK1PVE2KM7:TR?= MXzTRW5ITVJ?
HT-144 NEeyfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWwTWM2OD1yLkK2NVkyKM7:TR?= NHzzcmdUSU6JRWK=
LAN-6 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33iO2lEPTB;MD6yOlM1QCEQvF2= M4[w[nNCVkeHUh?=
EW-18 M2HPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfmZYZKSzVyPUCuNlcxODFizszN NVXMSXJoW0GQR1XS
LS-1034 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES4d|BKSzVyPUCuNlcyOzJizszN MlXIV2FPT0WU
EW-11 NHyy[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fuVWlEPTB;MD6yPFQ{OiEQvF2= NEPIPWRUSU6JRWK=
SNU-C1 MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPyfYRxUUN3ME2wMlI6OzF|IN88US=> MnXOV2FPT0WU
RS4-11 NFeyUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zEemlEPTB;MD6zN|c2QCEQvF2= NHLyRmVUSU6JRWK=
ES4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrtRYJPUUN3ME2wMlQyODN6IN88US=> NIDPcI5USU6JRWK=
COLO-320-HSR NXjwcHdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOwdZhKSzVyPUCuOFE{PjhizszN NUOzPXl{W0GQR1XS
NB10 M3jMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwNEW0N|ch|ryP M3\aVnNCVkeHUh?=
BFTC-905 NFvJOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwNE[3OVgh|ryP NHXpTphUSU6JRWK=
A375 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInoeWNKSzVyPUCuOFc3OTdizszN NGDvd3dUSU6JRWK=
SJRH30 NXfSe3g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fqVGlEPTB;MD61NFgzOiEQvF2= M1P3Z3NCVkeHUh?=
NOS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[4TWM2OD1yLkWyNlY4KM7:TR?= NH30[4hUSU6JRWK=
SIG-M5 MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNUO1OVch|ryP MmTQV2FPT0WU
DOK MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq2fZVKSzVyPUCuOVU3KM7:TR?= MlXXV2FPT0WU
NB69 NWn1UVdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzp[VJKSzVyPUCuOVgzPTdizszN MnjpV2FPT0WU
SK-NEP-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTV[ZdsUUN3ME2wMlYxOjN4IN88US=> NVW2cZlpW0GQR1XS
SK-MM-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwNkW0PVEh|ryP M2exTHNCVkeHUh?=
NCI-H358 NFjaN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLzTWM2OD1yLk[3NFgzKM7:TR?= NULk[GZ5W0GQR1XS
RH-1 NVK0O5ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DxTGlEPTB;MD63OFg2QSEQvF2= NWLOUmJnW0GQR1XS
NH-12 NEnmZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nqV2lEPTB;MD63OlA1PiEQvF2= M1X2dHNCVkeHUh?=
TE-12 NGDqU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz0XmJXUUN3ME2wMlc3PDh4IN88US=> NXPmXpVtW0GQR1XS
COLO-668 MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj4TWM2OD1yLki0OlY3KM7:TR?= NUjrPWtVW0GQR1XS
PANC-08-13 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWwTWM2OD1yLki2N|c4KM7:TR?= NUf3c2JbW0GQR1XS
HCC2998 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT6TWM2OD1yLki4NlY{KM7:TR?= NHW1NHZUSU6JRWK=
ABC-1 MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwOUCzOVIh|ryP MXfTRW5ITVJ?
ES6 NXfxSnJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDRTHllUUN3ME2wMlkyODZ4IN88US=> NUP4b3RLW0GQR1XS
SNU-387 NFzZS|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M370O2lEPTB;MD65PVM6OyEQvF2= NFWyR2NUSU6JRWK=
CMK MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHyTHhpUUN3ME2wMlk6QTJ7IN88US=> M{\wTHNCVkeHUh?=
SJSA-1 NELOcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwMEO2OVMh|ryP MljGV2FPT0WU
SIMA NUnaT4ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC2UIdKSzVyPUGuNFY5OjVizszN NIrqS|hUSU6JRWK=
ES3 M1LHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3pS4pKSzVyPUGuNVIzQTdizszN NV;NXIZDW0GQR1XS
IGROV-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMUW0OFQh|ryP M1ntNXNCVkeHUh?=
MEL-JUSO NIW2VWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;KbGVKSzVyPUGuNVU4PTlizszN M2nKVnNCVkeHUh?=
T84 NUjNXnkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfRXohKSzVyPUGuNlA6OTRizszN M4LLU3NCVkeHUh?=
CAL-85-1 NX;qVHRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfpRoRKSzVyPUGuNlMyOzhizszN Mm\xV2FPT0WU
RD MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLvOmF{UUN3ME2xMlI3PDV3IN88US=> NIK0XmlUSU6JRWK=
TE-8 NGPtXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFwM{G0OlIh|ryP M1zKU3NCVkeHUh?=
L-363 NYr1RmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTFwM{SyNFgh|ryP MlvwV2FPT0WU
EKVX MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S1[mlEPTB;MT6zOFU3QCEQvF2= Ml\uV2FPT0WU
SK-MEL-3 NUHDRnV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6zRnBZUUN3ME2xMlQ5PTV4IN88US=> NEHkc|VUSU6JRWK=
TGBC24TKB NEG2cnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2juWWlEPTB;MT61NFE6OyEQvF2= NFzjWnNUSU6JRWK=
NCI-H1770 NH\jOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\CXYNKSzVyPUGuOVEyOTNizszN NHW2SGVUSU6JRWK=
HuH-7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TwfGlEPTB;MT62NFA6QCEQvF2= NVX0W|E{W0GQR1XS
HL-60 M33x[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFwNk[5Nlgh|ryP MlXGV2FPT0WU
TE-1 NVfGfndPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVWyTJV5UUN3ME2xMlcxQTR3IN88US=> M3\n[nNCVkeHUh?=
LC-2-ad M{\sZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTHUWR1UUN3ME2xMlc{QDh5IN88US=> MYPTRW5ITVJ?
LB647-SCLC NVTsbZIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFwN{[1PFMh|ryP NWWyPZhkW0GQR1XS
NCI-H2171 NXvp[HhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fhXmlEPTB;MT63O|cyPiEQvF2= MV7TRW5ITVJ?
SK-PN-DW NWq1dGwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwOUGyPVgh|ryP MnnKV2FPT0WU
MC-IXC M2nHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETvbVhKSzVyPUGuPVg6QCEQvF2= M17CcHNCVkeHUh?=
LS-513 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGyWmszUUN3ME2yMlA2OzB3IN88US=> NHfaWXVUSU6JRWK=
EW-3 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7W[XJtUUN3ME2yMlA6QDR2IN88US=> MmDUV2FPT0WU
OPM-2 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\kc3loUUN3ME2yMlExOiEQvF2= MWHTRW5ITVJ?
LP-1 NVjteJBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HSWmlEPTB;Mj6yOVgxPyEQvF2= NYryRXYyW0GQR1XS
LU-134-A MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknJTWM2OD1{LkK3O{DPxE1? M3HEPHNCVkeHUh?=
CP66-MEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJwMkmwNVQh|ryP M1nJRnNCVkeHUh?=
HCC1143 NHnuVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCwTWM2OD1{LkS1N|Y5KM7:TR?= MVnTRW5ITVJ?
LOXIMVI MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLGTWM2OD1{Lk[wNlEh|ryP NFjOR5FUSU6JRWK=
TE-10 M3K0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvyTWM2OD1{LkewPFM5KM7:TR?= Mo\IV2FPT0WU
NCI-H1882 NXPVPZluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fBRmlEPTB;Mj63OVIzPyEQvF2= MkXXV2FPT0WU
CHP-126 NGi0R|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn3TWM2OD1{Lke2N|E4KM7:TR?= MUjTRW5ITVJ?
NCI-H1623 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCxTWM2OD1{LkmyNFI1KM7:TR?= MYDTRW5ITVJ?
GB-1 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXyzfnpsUUN3ME2yMlk{PDB2IN88US=> NFvodpRUSU6JRWK=
RCC10RGB NVSxVo9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwOUWyPFEh|ryP MmnWV2FPT0WU
NCI-H2141 NEPoToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwOU[4PVYh|ryP MoXXV2FPT0WU
GI-ME-N Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7zXI5KSzVyPUOuNFA2PjVizszN MlnhV2FPT0WU
NCI-H526 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1qxOWlEPTB;Mz6wOFA5PSEQvF2= NEHGOI5USU6JRWK=
NCI-H747 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\LfWlEPTB;Mz6wOFk6OiEQvF2= Mor0V2FPT0WU
SNU-423 NGnm[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwMkCzNVMh|ryP MUPTRW5ITVJ?
A427 MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnuUmNKSzVyPUOuNlU3QTlizszN M4P5OnNCVkeHUh?=
CAL-12T MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjQTWM2OD1|LkSwO|E{KM7:TR?= NIXye4dUSU6JRWK=
LU-99A M1jzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LYWGlEPTB;Mz60O|ExPSEQvF2= MXjTRW5ITVJ?
MS-1 Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTNwNUO0Nlkh|ryP M{jwS3NCVkeHUh?=
SK-LU-1 Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLTTWM2OD1|Lke2Nlk2KM7:TR?= NYLiWWlCW0GQR1XS
SW837 M{HBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLwTWM2OD1|Lke2N|M{KM7:TR?= MVjTRW5ITVJ?
ES8 M3zYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPKVmdKSzVyPUOuPFM5PzdizszN NHi0PVFUSU6JRWK=
MZ2-MEL MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfXNotKSzVyPUOuPVIxQDZizszN NUDLc4J4W0GQR1XS
TGW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnyTWM2OD12LkCxN|EyKM7:TR?= M1;MW3NCVkeHUh?=
GP5d NX31[XBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfFTWM2OD12LkC1N|YzKM7:TR?= M3[2OHNCVkeHUh?=
BB49-HNC M1O3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DxR2lEPTB;ND6xOVIyOyEQvF2= MXzTRW5ITVJ?
NB13 NFLF[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfwTWM2OD12LkK2PFg4KM7:TR?= Moq5V2FPT0WU
NTERA-S-cl-D1 NGT1fVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PJOWlEPTB;ND6yPFYyPSEQvF2= NGH6VZdUSU6JRWK=
NCI-H1648 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTRwMkm4NVkh|ryP MknLV2FPT0WU
LCLC-103H NHLxS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDNc4ZMUUN3ME20MlMzOTl3IN88US=> M{W5dnNCVkeHUh?=
LS-411N M3OweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTRwNES4PFUh|ryP MUfTRW5ITVJ?
NCI-H1092 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\tTWM2OD12LkS1Olg4KM7:TR?= NInzNWlUSU6JRWK=
PANC-10-05 NV7aSmJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTKTWM2OD12Lk[5PFQh|ryP M3LEOHNCVkeHUh?=
DK-MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTRwOEC5N|Mh|ryP MlHuV2FPT0WU
OVCAR-5 NHr4OJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLzTWM2OD12LkixNlI3KM7:TR?= MmrBV2FPT0WU
CAL-39 M2K0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTRwOEe2O{DPxE1? Mm\wV2FPT0WU
TE-441-T NHLPVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TRXmlEPTB;ND65NFU{PyEQvF2= M2TNSXNCVkeHUh?=
MOLT-16 MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDwb3VKSzVyPUSuPVUzPTNizszN M4rWXXNCVkeHUh?=
MCF7 Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjGR3poUUN3ME21MlE1PTF5IN88US=> NHzrdW1USU6JRWK=
CAPAN-1 MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH6N3pKSzVyPUWuNlU4ODdizszN NHrW[2FUSU6JRWK=
PSN1 Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTVwMkeyN|Uh|ryP NIjDOlNUSU6JRWK=
NCI-H292 M1H0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvPTWM2OD13LkOwNFQ1KM7:TR?= MVPTRW5ITVJ?
CPC-N NG[4eYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTVwM{m0NVkh|ryP MVjTRW5ITVJ?
DoTc2-4510 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{O2UmlEPTB;NT60OVM4OSEQvF2= NVnCe4pkW0GQR1XS
LB1047-RCC NEXnZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTVwNUW5N|Mh|ryP NUDMOJRwW0GQR1XS
MHH-ES-1 NHzvNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPETWM2OD13LkW5PVA4KM7:TR?= MkLxV2FPT0WU
NMC-G1 MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\3OFJIUUN3ME21MlcxOjJ5IN88US=> NYLvTlVpW0GQR1XS
SW1710 NV;nfFU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jmUWlEPTB;NT63OFc2OSEQvF2= MX7TRW5ITVJ?
YAPC MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3nTWM2OD13Lke2NlAyKM7:TR?= M3r5N3NCVkeHUh?=
22RV1 NHf4OlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXRTWM2OD13LkiwNFE6KM7:TR?= NIT4NllUSU6JRWK=
COLO-679 NXXxRmdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nRWWlEPTB;NT64PFk1QCEQvF2= NViyXolnW0GQR1XS
TCCSUP NFrGUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITnUWpKSzVyPUWuPVMzPTlizszN MonLV2FPT0WU
C2BBe1 NGTubFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rXT2lEPTB;NT65N|k4KM7:TR?= Mo[4V2FPT0WU
TE-15 NWHac41ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H0V2lEPTB;Nj6wOlYxPSEQvF2= M17XSnNCVkeHUh?=
SCLC-21H NV;Rbo9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWThfmhGUUN3ME22MlExQDR|IN88US=> NH;PeJdUSU6JRWK=
EoL-1-cell M{[xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3BTZJKSzVyPU[uNVY2PjNizszN NHvWNIlUSU6JRWK=
NKM-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHWR|RKSzVyPU[uNVY4OSEQvF2= NXnDcXA1W0GQR1XS
NCI-H1304 M4rvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXiNplKSzVyPU[uNlc1OjhizszN MnTsV2FPT0WU
NB6 MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXzc4ZKSzVyPU[uNlk3OjJizszN MmPVV2FPT0WU
NALM-6 NVPvWld7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jZemlEPTB;Nj6zN|I{KM7:TR?= MWPTRW5ITVJ?
NCI-H522 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvPTWM2OD14LkOzN|A3KM7:TR?= M3rNS3NCVkeHUh?=
MV-4-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\WU|dKSzVyPU[uN|cxPzlizszN NYrJPYZOW0GQR1XS
LB2241-RCC NX;xRotZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\XZmlEPTB;Nj6zPFY3PyEQvF2= MU\TRW5ITVJ?
NCI-H1417 NWPIdYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;UTWM2OD14LkSwPFQ4KM7:TR?= MVfTRW5ITVJ?
HT-1197 NHrndFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTZwNUexNlIh|ryP NULD[4FsW0GQR1XS
P30-OHK MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;ZTWM2OD14Lk[yO|ch|ryP MnP3V2FPT0WU
ALL-PO NWjEdFJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\vSphKSzVyPU[uO|E6OTZizszN M3vYPHNCVkeHUh?=
OVCAR-4 MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYizclJkUUN3ME22Mlc2PDB3IN88US=> Mnn5V2FPT0WU
HCC2157 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISwPZdKSzVyPU[uO|c1PzVizszN MomxV2FPT0WU
NCI-H838 M2LFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH61fYRKSzVyPU[uPVY1QSEQvF2= MVvTRW5ITVJ?
NCI-H1299 NIjPdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXxclRKSzVyPU[uPVcxQSEQvF2= MkDWV2FPT0WU
SW954 NVrnc3JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DNSmlEPTB;Nz6yNFA3QCEQvF2= MVTTRW5ITVJ?
NCI-H441 NUfpOWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnoTWM2OD15LkO0NFY2KM7:TR?= M1vzNXNCVkeHUh?=
SK-MEL-2 M3PvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrCTWM2OD15LkS4N|c{KM7:TR?= MlLxV2FPT0WU
KARPAS-45 Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;mTWM2OD15Lk[1PVI6KM7:TR?= MoS3V2FPT0WU
CAL-54 NHn6To1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDWe5J4UUN3ME23MlgzQTd5IN88US=> NHHiTodUSU6JRWK=
KYSE-180 M3u5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TZSmlEPTB;Nz64PFk1OSEQvF2= M{nxdnNCVkeHUh?=
NCI-H187 Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPKcZRKSzVyPUeuPVU6PDdizszN NEPPZ3RUSU6JRWK=
RT-112 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n3cGlEPTB;OD6wPVY4PyEQvF2= NYTxblhiW0GQR1XS
NCI-H1437 NWL0d2VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7FUWxXUUN3ME24MlA6Pzl3IN88US=> MVvTRW5ITVJ?
SNU-449 NELZOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRThwMkiyO|Ih|ryP NX\ZemhSW0GQR1XS
HCC1187 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFiyVYtKSzVyPUiuNlk{QTFizszN NEjKTI9USU6JRWK=
NCI-H2030 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3O[GFMUUN3ME24MlM4PzF2IN88US=> NWDKTlhHW0GQR1XS
HuO-3N1 NInHfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLSOHlKSzVyPUiuN|c5PDRizszN MojSV2FPT0WU
COLO-792 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zGd2lEPTB;OD60NVUzPyEQvF2= M4POXHNCVkeHUh?=
MIA-PaCa-2 NHjBU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP1[oJZUUN3ME24Mlg2PTB6IN88US=> MlvWV2FPT0WU
SK-N-FI MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXCU|JKSzVyPUmuNFQzPSEQvF2= MnfCV2FPT0WU
MMAC-SF NV\jW29sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL4dGhpUUN3ME25MlA6PzVzIN88US=> M3\UXnNCVkeHUh?=
NCI-H28 NH\ITmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP4TWM2OD17LkGwOFY6KM7:TR?= NI[5TGpUSU6JRWK=
ETK-1 M4TRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPMTWM2OD17LkK5PVc1KM7:TR?= MUHTRW5ITVJ?
NCI-H1993 MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTlwNESyOlEh|ryP MWDTRW5ITVJ?
no-11 M2C3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ThNWlEPTB;OT60O|EzKM7:TR?= MX7TRW5ITVJ?
ChaGo-K-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrHWHFxUUN3ME25MlUyPTh|IN88US=> NXTrSoxkW0GQR1XS
NCCIT NGfrd5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnmeINKSzVyPUmuOVMyPjlizszN NIjmXodUSU6JRWK=
SAS NWTkXWVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fjeGlEPTB;MUCuNlQ5KM7:TR?= NU\FPJZ7W0GQR1XS
A673 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFyLkO3NFQh|ryP Ml\qV2FPT0WU
NCI-H1522 MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFyLkO3NFch|ryP MnnPV2FPT0WU
NCI-H810 M2XKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\vNFZVUUN3ME2xNE4{QTB5IN88US=> Ml\QV2FPT0WU
IST-MES1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXzfIZCUUN3ME2xNE41PTZ2IN88US=> MWnTRW5ITVJ?
GR-ST M4Hwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDFUmU2UUN3ME2xNE42ODJ2IN88US=> MWHTRW5ITVJ?
SUP-T1 NWW1Wlk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nQU2lEPTB;MUCuO|MyPyEQvF2= MmmyV2FPT0WU
NB5 NYPqUm1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vPN2lEPTB;MUCuPVAzOiEQvF2= NX;CdVN4W0GQR1XS
MZ1-PC NXLD[FY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv4e5RKSzVyPUGwMlk2PzFizszN NGrpVVhUSU6JRWK=
SK-CO-1 M2fiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\pTWM2OD1zMD65PVMyKM7:TR?= MWLTRW5ITVJ?
Capan-2 NGXmOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LZOWlEPTB;MUGuN|E6QCEQvF2= NWP2XJNyW0GQR1XS
697 NEDOfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPNZW9IUUN3ME2xNU43PzV5IN88US=> NGDWfJdUSU6JRWK=
REH NXvVcHZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vzeWlEPTB;MUGuO|Q2OSEQvF2= MVPTRW5ITVJ?
GI-1 NYjw[YtYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe1[GU5UUN3ME2xNU45PjF3IN88US=> NE\EWZlUSU6JRWK=
BB65-RCC M1rj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T0OmlEPTB;MUKuNFkyPiEQvF2= NWrtclg6W0GQR1XS
NCI-H1651 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXoUYhKSzVyPUGyMlI1PzhizszN MkfzV2FPT0WU
NCI-H1618 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfFT2JKSzVyPUGyMlM6PzZizszN NITMR2dUSU6JRWK=
NCI-H2081 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPTTWM2OD1zMj62NVQyKM7:TR?= Mm\VV2FPT0WU
GCIY MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTF{LkeyNVMh|ryP M{jEenNCVkeHUh?=
NY NXznXG9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vCdmlEPTB;MUOuNFY1OyEQvF2= NH3ib4FUSU6JRWK=
PANC-03-27 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\6bGlEPTB;MUOuNFgxPyEQvF2= M{nwXXNCVkeHUh?=
BHY NUf2N5dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[xN5M1UUN3ME2xN{4zOTJzIN88US=> M{jzfXNCVkeHUh?=
SK-OV-3 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrE[I1KSzVyPUGzMlM4PjNizszN NH7tZ5dUSU6JRWK=
5637 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonMTWM2OD1zMz63O|U6KM7:TR?= NIHRV|JUSU6JRWK=
LC-1F MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjFcm1KSzVyPUG0MlA{PTZizszN M3rs[HNCVkeHUh?=
SNB75 NEDRR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fCTWlEPTB;MUSuNFM5OyEQvF2= NV\SdmFDW0GQR1XS
CHP-212 MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPGTWM2OD1zND6wOFY1KM7:TR?= NFXjN2JUSU6JRWK=
HT-1376 Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLLN2hzUUN3ME2xOE4yOTJ4IN88US=> NI\oWmNUSU6JRWK=
MONO-MAC-6 M2L2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF2LkG1NFIh|ryP MXXTRW5ITVJ?
CA46 Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XzXmlEPTB;MUSuNVgzPyEQvF2= M{nBdnNCVkeHUh?=
SCC-15 NV6yNJdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn6RW1XUUN3ME2xOE42PTh|IN88US=> NIC4VI1USU6JRWK=
ATN-1 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF2Lk[2Nlch|ryP MVXTRW5ITVJ?
NCI-H2405 NVPabol7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;1dYVKSzVyPUG0MlgyPTdizszN NIj5[ZBUSU6JRWK=
NCI-H716 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF2Lki0PVMh|ryP NVW3SI1SW0GQR1XS
SW620 NUjCTZJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHCVYVKSzVyPUG0MlkxOTRizszN NGjDWYhUSU6JRWK=
NCI-H226 MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTTellKSzVyPUG0MlkxQDVizszN NF3PfoVUSU6JRWK=
SW962 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PwXWlEPTB;MUSuPVQ{OiEQvF2= NE[3[3lUSU6JRWK=
KYSE-150 NUjYTlh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXvTHBKSzVyPUG0Mlk2PSEQvF2= MnXiV2FPT0WU
OCUB-M NVHKZWhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHLTWM2OD1zND65PFg{KM7:TR?= M4[1OHNCVkeHUh?=
ES7 M3jYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HhdGlEPTB;MUWuNFk5PCEQvF2= NGDafJVUSU6JRWK=
SW1463 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT4OoltUUN3ME2xOU41OjJ|IN88US=> MV;TRW5ITVJ?
CAKI-1 NVy4VGhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXXVZA6UUN3ME2xOU42OzR4IN88US=> NHezXWdUSU6JRWK=
MKN28 M2PVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vq[GlEPTB;MUWuOVQ4QSEQvF2= MkLvV2FPT0WU
SW13 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrDTWM2OD1zNT62NVgh|ryP NFXJcoRUSU6JRWK=
A3-KAW NWfZWm56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn6[ldKSzVyPUG1Mlk3QTdizszN M2KyUXNCVkeHUh?=
LU-65 NFTEbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF3Lkm3Olgh|ryP NXPWSW5wW0GQR1XS
Calu-1 NVW3e3lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX4Z49KSzVyPUG2MlA{PjhizszN MoXOV2FPT0WU
ST486 NFrkWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmSwTWM2OD1zNj6wOFMyKM7:TR?= MV3TRW5ITVJ?
BB30-HNC MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HPb2lEPTB;MU[uNVI1PiEQvF2= NIjINGlUSU6JRWK=
EGI-1 NE\kcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW0PFd5UUN3ME2xOk41PDZizszN Mn33V2FPT0WU
SH-4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml62TWM2OD1zNj60O|MyKM7:TR?= NYPsRZRPW0GQR1XS
MN-60 NYPBNI8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfCW45KSzVyPUG3MlIzQTdizszN M2q4RnNCVkeHUh?=
MPP-89 M1SxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\HTWM2OD1zNz6yOFU6KM7:TR?= NWnXfW57W0GQR1XS
A2780 NXuwdXM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL3U2VNUUN3ME2xO{41OTN7IN88US=> M3fydXNCVkeHUh?=
Daoy NGDtUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33B[2lEPTB;MUeuOFY6PSEQvF2= M4Xoe3NCVkeHUh?=
NCI-H2126 NVzMWGpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzONoE6UUN3ME2xO{41PzdzIN88US=> Mln1V2FPT0WU
NCI-H1563 NHvHXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknxTWM2OD1zNz60PVE4KM7:TR?= M3TnTHNCVkeHUh?=
8-MG-BA NUHTU2xUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnPTWM2OD1zNz62OlQ5KM7:TR?= NH3mbYtUSU6JRWK=
786-0 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DNOWlEPTB;MUeuPFM2OyEQvF2= MWHTRW5ITVJ?
AM-38 NUXGNHJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nMTmlEPTB;MUeuPVMxPiEQvF2= M37GNnNCVkeHUh?=
COLO-824 M4f5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\neGlEPTB;MUiuOFQ{PiEQvF2= MlvGV2FPT0WU
SK-MEL-30 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWS1WlJiUUN3ME2xPE42ODh{IN88US=> MWjTRW5ITVJ?
CESS MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP6V3BlUUN3ME2xPE44PjB7IN88US=> NGn4UoFUSU6JRWK=
BL-70 NEHyN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O1VWlEPTB;MUiuPFE2PiEQvF2= MlTUV2FPT0WU
NCI-H2170 NUjKWmlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC1PFlKSzVyPUG4MlkyPzlizszN NH7GcZJUSU6JRWK=
HT-3 M2ezfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfz[nJ3UUN3ME2xPE46QDNizszN NXSyVnF5W0GQR1XS
BOKU MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:5UoNKSzVyPUG5MlA{QDFizszN MXzTRW5ITVJ?
HPAF-II NHq3bmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHHNZRKSzVyPUG5MlMxOTVizszN M1exXnNCVkeHUh?=
KGN M37yXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O3VGlEPTB;MUmuOFc3PSEQvF2= M{PQU3NCVkeHUh?=
MC-CAR NUjte2hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLPTWM2OD1zOT62N|E{KM7:TR?= MUfTRW5ITVJ?
BHT-101 MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF7Lke3O{DPxE1? MkPLV2FPT0WU
SW1783 NHnPdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHZeZd7UUN3ME2xPU44QDB4IN88US=> NEjCNodUSU6JRWK=
KP-N-YN NXjBenE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJyLkCyOlIh|ryP MoXVV2FPT0WU
LU-165 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJyLkW1O|Eh|ryP M13icHNCVkeHUh?=
GOTO MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;GTWM2OD1{MD62OFUyKM7:TR?= NIi3WlFUSU6JRWK=
EFM-19 Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jaXWlEPTB;MkGuNFcyPiEQvF2= MnP2V2FPT0WU
CTV-1 NXrSUnNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;lTWM2OD1{MT6xNFU1KM7:TR?= MX3TRW5ITVJ?
HEL NES3Z2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJzLkSyNVYh|ryP Mn6yV2FPT0WU
SNU-C2B NWDMfpFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJzLkSyOkDPxE1? Mlv0V2FPT0WU
ECC4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml6yTWM2OD1{MT63NFch|ryP NXnYVIpNW0GQR1XS
NEC8 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDFOYRmUUN3ME2yNU45OzZ6IN88US=> M1mzb3NCVkeHUh?=
KMOE-2 Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJzLki5NlEh|ryP MoW4V2FPT0WU
NCI-H524 NEj4bXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M374[mlEPTB;MkKuNFgxQCEQvF2= MmXFV2FPT0WU
WSU-NHL NIfQVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ{LkG1O|ch|ryP M3f4eXNCVkeHUh?=
SF126 M33oNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT4TWM2OD1{Mj6yOFY6KM7:TR?= NXXyfIxpW0GQR1XS
HOP-92 M1XZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJ{LkOxOlch|ryP MkTBV2FPT0WU
CTB-1 MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrN[VVKSzVyPUKyMlQ3PzdizszN NIfVUJlUSU6JRWK=
KYSE-270 NEH4NoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJ{LkmzOVch|ryP NVy1OXJNW0GQR1XS
SK-MEL-24 M3ToS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJ|LkG4O{DPxE1? Ml\qV2FPT0WU
Calu-3 MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O4NGlEPTB;MkOuNlEzQCEQvF2= NF\HZXZUSU6JRWK=
GAMG MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPjUItVUUN3ME2yN{4zOzZ5IN88US=> NIrBV3VUSU6JRWK=
SW1573 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJ|Lke0NVUh|ryP MkmyV2FPT0WU
MHH-NB-11 NX;ENZJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDzTWM2OD1{ND6wNVk1KM7:TR?= MVfTRW5ITVJ?
TK10 NEHXbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O5Z2lEPTB;MkSuOVAyOyEQvF2= MkC1V2FPT0WU
LB373-MEL-D NHTqV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X4e2lEPTB;MkSuOlA3PCEQvF2= MWnTRW5ITVJ?
KALS-1 NXfVWXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvyTWM2OD1{ND63N|I4KM7:TR?= M17ld3NCVkeHUh?=
HUTU-80 NWjROld6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G0R2lEPTB;MkWuPFA{OiEQvF2= NGfLOY1USU6JRWK=
HuP-T3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ4LkG2O|Qh|ryP M3Xn[3NCVkeHUh?=
OE19 NFjtNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjSZ3BmUUN3ME2yOk4zOTV|IN88US=> MnfXV2FPT0WU
J82 NIrJRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXTTWM2OD1{Nj6yOFcyKM7:TR?= MV7TRW5ITVJ?
DU-4475 NILCTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnjeXJKSzVyPUK2MlM5OTlizszN NV\tdlJjW0GQR1XS
DMS-53 M2r4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrqNJNKSzVyPUK2MlUyOzhizszN M1nofnNCVkeHUh?=
COLO-741 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vLXGlEPTB;Mk[uPFM1PCEQvF2= M1fYNXNCVkeHUh?=
SW48 M3\FW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJ4Lki4NkDPxE1? NH7ve4JUSU6JRWK=
IGR-1 NEi0Vm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJ4LkmzN|Qh|ryP MnO4V2FPT0WU
639-V MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ5LkCyOFUh|ryP M2TQWXNCVkeHUh?=
LK-2 NEj2eGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG0T4xWUUN3ME2yO{41OTRzIN88US=> M1PsUnNCVkeHUh?=
NCI-H2347 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmThTWM2OD1{Nz65Olk6KM7:TR?= NXW5UmVXW0GQR1XS
NCI-H2228 M1HIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGzTWM2OD1{OD6wPVA2KM7:TR?= NFfXN|ZUSU6JRWK=
LS-123 M1nHN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLPTWM2OD1{OD6xNlYzKM7:TR?= NGH3ToVUSU6JRWK=
U031 NVnY[FNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3wRplbUUN3ME2yPE4zPTJizszN MkLYV2FPT0WU
NCI-H1792 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXaTWM2OD1{OD60O|IyKM7:TR?= MWjTRW5ITVJ?
NCI-H2087 M{G2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv3TWM2OD1{OD63OVUzKM7:TR?= NGnrRZVUSU6JRWK=
NCI-H2342 NWG1fmd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJ7LkWyNFgh|ryP NI[2bYhUSU6JRWK=
SW626 MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrH[lJlUUN3ME2yPU44PTZizszN NI\SWnFUSU6JRWK=
LB2518-MEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m5N2lEPTB;MkmuPFE2KM7:TR?= NUGzbWxbW0GQR1XS
RXF393 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LMSGlEPTB;M{CuNFk2OiEQvF2= MkXqV2FPT0WU
LC4-1 M2jIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvDTWM2OD1|MD6zNFkzKM7:TR?= Mn;KV2FPT0WU
NCI-H1694 NETXTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDleG9KSzVyPUOwMlY3OjRizszN MkXYV2FPT0WU
K5 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDITWM2OD1|MD65O|AzKM7:TR?= MXrTRW5ITVJ?
HDLM-2 NYOzbHEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITsdY5KSzVyPUOwMlk4OjVizszN NI\POIZUSU6JRWK=
BCPAP MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;5N3FKSzVyPUOxMlg{PzlizszN NWq5cW5[W0GQR1XS
BC-3 M4H3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu5TWM2OD1|Mj6xOFA{KM7:TR?= NFfVco1USU6JRWK=
LB996-RCC MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq5fpk{UUN3ME2zNk4zOzV6IN88US=> MknUV2FPT0WU
NCI-H2009 NH3DdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELjd2JKSzVyPUOyMlQ6QDFizszN NH30UlVUSU6JRWK=
HTC-C3 NGjiNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu4elZlUUN3ME2zN{44PTF7IN88US=> M{n5e3NCVkeHUh?=
LAMA-84 NVfP[mxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fSTWlEPTB;M{SuOFQxPyEQvF2= Mor3V2FPT0WU
CCRF-CEM M3;UVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLRcllqUUN3ME2zOE42PzF3IN88US=> MVPTRW5ITVJ?
AN3-CA NYPPb2d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL4OGJwUUN3ME2zOU4xPTZ6IN88US=> NWTm[ZBLW0GQR1XS
NCI-H1734 NYTXV|NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTN3LkK1OlEh|ryP NULHRm1RW0GQR1XS
Ca-Ski Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;sVFlKSzVyPUO1MlQyODFizszN Mk\EV2FPT0WU
U-266 M1vVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrZRlBKSzVyPUO1MlYyOTRizszN NG\vPJJUSU6JRWK=
SBC-5 M4TlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\QU2lEPTB;M{WuO|c5OSEQvF2= M{jzVHNCVkeHUh?=
GT3TKB NIfRUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTN5LkGxOUDPxE1? Mn;MV2FPT0WU
MDA-MB-175-VII MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\UTWM2OD1|Nz6yNlQ5KM7:TR?= MoLzV2FPT0WU
PFSK-1 NUXUcoxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zVemlEPTB;M{euNlQ{PSEQvF2= NFLOfZZUSU6JRWK=
IMR-5 NGfMXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P0emlEPTB;M{euNlQ5PyEQvF2= M{eyc3NCVkeHUh?=
Daudi MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTvUYVJUUN3ME2zO{4{PTl5IN88US=> NYWxZllSW0GQR1XS
A498 NFm5fHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrWUGZKSzVyPUO3MlczOThizszN MlXaV2FPT0WU
SCC-4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTN5Lke4OFMh|ryP NX3wU|hGW0GQR1XS
COLO-680N M13URWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWySVZlUUN3ME2zPE4zQDh3IN88US=> NYLGcYVxW0GQR1XS
SK-MES-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrEd2xKSzVyPUO4MlMzOTVizszN M3nXVXNCVkeHUh?=
SR MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLvZmxKSzVyPUO4MlU1QTVizszN MmTGV2FPT0WU
LNCaP-Clone-FGC NHPDXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTN6LkW2N|ch|ryP NE\6b4pUSU6JRWK=
SK-HEP-1 NHfmdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTN6Lke4NlIh|ryP MWHTRW5ITVJ?
BPH-1 M1L6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TJVWlEPTB;M{iuPFMzQSEQvF2= NFXYVWVUSU6JRWK=
NCI-H1755 MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTN7LkW4NVch|ryP MnPGV2FPT0WU
LXF-289 NHTrXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL1[ld[UUN3ME2zPU45ODh2IN88US=> MnqyV2FPT0WU
SW1088 NXfjWmc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf5eld6UUN3ME20NE4zOTB5IN88US=> MmnoV2FPT0WU
MOLT-4 NYnuO3VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTRyLkK5NFEh|ryP NGq4VIJUSU6JRWK=
AsPC-1 M1u3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW2PZZKSzVyPUSwMlQ2QDNizszN M{DpVXNCVkeHUh?=
HOP-62 NXz1PVZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorzTWM2OD12MD62OVY5KM7:TR?= M{LsdHNCVkeHUh?=
A172 M1Tqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTrR4RJUUN3ME20NE45PTFzIN88US=> NUX3TXhyW0GQR1XS
SN12C MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTRyLkmzPFUh|ryP MmjWV2FPT0WU
MDA-MB-231 M3e0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYqze5pqUUN3ME20NE46QDl6IN88US=> NWjBc5h3W0GQR1XS
RPMI-2650 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\y[I9KSzVyPUSxMlE2QTNizszN MYHTRW5ITVJ?
KYSE-140 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[xWVlKSzVyPUSxMlgyOjNizszN M3P1c3NCVkeHUh?=
KINGS-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXNOoZKSzVyPUSyMlQ3QTdizszN M2nOWHNCVkeHUh?=
HSC-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTR{Lk[2OlEh|ryP NXG3Nm8yW0GQR1XS
PC-14 MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37afWlEPTB;NEOuNVg5OiEQvF2= MmXyV2FPT0WU
COR-L105 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3VSm9MUUN3ME20N{43PTB{IN88US=> MVTTRW5ITVJ?
BE-13 M2jkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTR2LkKzO|Eh|ryP MnWzV2FPT0WU
NCI-H661 M4nyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH1T2NKSzVyPUS0MlI6PThizszN M3ntc3NCVkeHUh?=
IST-MEL1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLzTWM2OD12ND6zOVk6KM7:TR?= MofDV2FPT0WU
HCC1806 NGHWWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrm[lFOUUN3ME20OE42QDd|IN88US=> M4j4fHNCVkeHUh?=
COLO-800 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn6TWM2OD12ND64OFU{KM7:TR?= M3TUPXNCVkeHUh?=
IST-SL2 M13mRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnKzTWM2OD12NT6xNlQ4KM7:TR?= NX;DNFR3W0GQR1XS
8305C MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XQVWlEPTB;NEWuN|A6KM7:TR?= MX7TRW5ITVJ?
UACC-62 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGwTWM2OD12Nj6yPFc2KM7:TR?= MUHTRW5ITVJ?
COR-L23 NXz6RnRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO5TWM2OD12Nz6xPVkh|ryP M1LpRXNCVkeHUh?=
EFE-184 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TqbWlEPTB;NEeuN|g5KM7:TR?= MVfTRW5ITVJ?
DMS-114 NE\TbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H2Z2lEPTB;NEeuOFE1QSEQvF2= Mm\6V2FPT0WU
KYSE-520 NEPRPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfBVWRKSzVyPUS4MlU{OTVizszN NXPjVHZCW0GQR1XS
SNG-M NGm5NmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LrZmlEPTB;NEmuOFM1KM7:TR?= M3KyVnNCVkeHUh?=
A2058 Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nP[WlEPTB;NEmuOFg5PSEQvF2= NH70TXRUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; 

PubMed: 26052929     


Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells.

p-IGF1R / IGF1R / p-mTOR / mTOR ; 

PubMed: 28440057     


Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot.

cleaved caspase-3 / cleaved PARP; 

PubMed: 28440057     


Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control.

pSrc(Y416) / Src; 

PubMed: 26515601     


A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis.

p-STAT3(Y705) / STAT3 ; 

PubMed: 26041671     


H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days.

pS6 / S6; 

PubMed: 21257723     


Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.

26052929 28440057 26515601 26041671 21257723
Immunofluorescence
FoxO1; 

PubMed: 27535223     


After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min.  A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.

27535223
Growth inhibition assay
Cell viability; 

PubMed: 26136493     


InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.

26136493
In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
- Collapse

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
- Collapse
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A
Smiles CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02546544 Completed Drug: Linsitinib Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01672736 Terminated Drug: ASP7487 Velcade Dexamethasone Multiple Myeloma University Health Network Toronto|Multiple Myeloma Research Consortium|Astellas Pharma Inc September 2012 Phase 1|Phase 2
NCT01529684 Completed Drug: radio-labeled OSI-906|Drug: OSI-906 Advanced Solid Tumors|Pharmacokinetics of 14C-OSI-906 Astellas Pharma Global Development Inc.|Astellas Pharma Inc March 19 2012 Phase 1
NCT01221077 Completed Drug: OSI-906|Drug: Erlotinib|Drug: Placebo NSCLC|Non Small Cell Lung Cancer Astellas Pharma Inc April 8 2011 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib|Linsitinib ic50|Linsitinib price|Linsitinib cost|Linsitinib solubility dmso|Linsitinib purchase|Linsitinib manufacturer|Linsitinib research buy|Linsitinib order|Linsitinib mouse|Linsitinib chemical structure|Linsitinib mw|Linsitinib molecular weight|Linsitinib datasheet|Linsitinib supplier|Linsitinib in vitro|Linsitinib cell line|Linsitinib concentration|Linsitinib nmr|Linsitinib in vivo|Linsitinib clinical trial|Linsitinib inhibitor|Linsitinib Protein Tyrosine Kinase inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID